TIDMDEMG
RNS Number : 6369R
Deltex Medical Group PLC
25 September 2017
25 September 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Share Options
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM") announces the grant of share
options to its executive directors under its Employee Share Option
Scheme and the exercise by an employee of 97,560 share options
under the Company's Enterprise Management Incentive scheme
('EMI').
Employee Share Option Scheme
The Board has approved the grant of 2,500,000 and 1,562,500
share options to Ewan Phillips and Jonathan Shaw respectively under
the Company's 2011 Executive Share Option Scheme. The exercise
price is 4 pence per share option, a premium of 23% over the
closing price on 22 September 2017. These share options may
ordinarily be exercised between September 2020 and September 2027
subject to relevant performance conditions which are based on
achieving certain levels of compound annual sales growth.
Confirmation of Directors interest in share options
Following the grant of EMI options above, the options held by
the Executive Directors are shown below:
Executive 2001 Executive 2011 Executive EMI Share
Director Share Scheme Share Scheme Scheme Total
Number Number Number Number
--------------- --------------- --------------- ---------- ----------
Ewan Phillips 1,000,000 5,250,000 2,995,954 9,245,954
Jonathan
Shaw - 1,562,500 404,762 1,967,262
--------------- --------------- --------------- ---------- ----------
Additional interests
Mr Phillips and Mr Shaw have beneficial interests in 2,921,051
and 262,931 ordinary shares in the Company respectively. Following
the share option exercise referred to above these holdings will
represent 0.93 per cent and 0.08 per cent of the issued ordinary
share capital of the Company.
Exercise of EMI share options
The Company has also issued 97,560 new Ordinary Shares of 1
pence each in the capital of the Company ("Ordinary Shares")
following the exercise of options by an employee granted under the
Company's EMI share option scheme. The options had an exercise
price of 1 pence per share and the notice of exercise was received
on 13 September 2017. Application has been made for the 97,560 new
Ordinary Shares to be admitted to trading on AIM ("Admission"), and
dealings are expected to commence on 29 September 2017. The new
Ordinary Shares will rank pari passu with the Company's existing
Ordinary Shares.
The total number of Ordinary Shares in issue following Admission
will be 313,213,367. The Company does not hold any shares in
treasury. Accordingly, the figure of 313,213,367 may be used by
shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company under the FCA's
Disclosure Guidance and Transparency Rules.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
The following notifications are made in accordance with Article
19 of the EU Market Abuse Regulation
1 Details of the person discharging managerial
responsibilities / person closely associated
a) Name Ewan Phillips
--------------------------- -----------------------------------
2 Reason for the notification
----------------------------------------------------------------
a) Position/status Executive Director
--------------------------- -----------------------------------
b) Initial notification Initial
/Amendment
--------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
----------------------------------------------------------------
a) Name Deltex Medical Group plc
--------------------------- -----------------------------------
b) LEI N/A
--------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------
a) Description of Conditional awards over
the financial instrument, Ordinary shares of 1p each
type of instrument in Deltex Medical Group
plc
Identification
code Identification code (ISIN)
for Deltex Medical Group
plc ordinary shares: GB0059337583
--------------------------- -----------------------------------
b) Nature of the transaction Grant of Share Options
--------------------------- -----------------------------------
c) Price(s) and volume(s) Conditional award over
2,500,000 shares under
the Deltex Medical Group
Executive Share Option
Scheme 2011
--------------------------- -----------------------------------
d) Aggregated information
- Aggregated volume
- Price
--------------------------- -----------------------------------
e) Date of the transaction 22 September 2017
--------------------------- -----------------------------------
f) Place of the transaction Grant of share awards occurred
outside of a trading venue.
--------------------------- -----------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
a) Name Jonathan Shaw
-------------------------- -----------------------------------
2 Reason for the notification
---------------------------------------------------------------
a) Position/status Executive Director
-------------------------- -----------------------------------
b) Initial notification Initial
/Amendment
-------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
---------------------------------------------------------------
a) Name Deltex Medical Group plc
-------------------------- -----------------------------------
b) LEI N/A
-------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------
a) Description of the Conditional awards over Ordinary
financial instrument, shares of 1p each in Deltex
type of instrument Medical Group plc
Identification code Identification code (ISIN)
for Deltex Medical Group
plc ordinary shares: GB0059337583
-------------------------- -----------------------------------
b) Nature of the transaction Grant of Share Options
-------------------------- -----------------------------------
c) Price(s) and volume(s) Conditional award over 1,562,500
shares under the Deltex Medical
Group Executive Share Option
Scheme 2011
-------------------------- -----------------------------------
d) Aggregated information
- Aggregated volume
- Price
-------------------------- -----------------------------------
e) Date of the transaction 22 September 2017
-------------------------- -----------------------------------
f) Place of the transaction Grant of share awards occurred
outside of a trading venue.
-------------------------- -----------------------------------
For further information, please contact:
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Ciaran Walsh
Joint Broker
Turner Pope Investments 0203 621 4120
(TPI) Ltd info@turnerpope.com
Ben Turner
James Pope
Financial Public Relations
IFC Advisory Ltd 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's ODM is the only technology to
measure continuously blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM. Randomised,
controlled trials using Doppler have demonstrated that early fluid
management intervention will reduce post-operative complications,
reduce intensive care admissions, and reduce the length of hospital
stay.
Company goal
ODM is increasingly recognised as a standard of care for
patients undergoing major surgery and in critical care. The broader
clinical area of haemodynamic management of which ODM is a core
constituent is also now becoming widely accepted as an important
major new medical modality. Consequently, the Company's focus is on
maximising value from the opportunities presented as enhanced
haemodynamic management is adopted into routine clinical practice
around the world.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,400 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHUSUNRBUAKUAR
(END) Dow Jones Newswires
September 25, 2017 02:01 ET (06:01 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024